SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 681.78+1.0%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (2756)11/21/2019 2:39:38 PM
From: Miljenko Zuanic  Read Replies (2) of 3557
 
High conc. Eylea patent application:
appft.uspto.gov
At 100mg/mL and up to 24w: <36. The method of claim 30 wherein the VEGF receptor fusion protein is administered in about 100 microliters or less, about 90 microliters, about 80 microliters, about 75 microliters, about 70 microliters, about 60 microliters or about 50 microliters.>....10 mg/9mg/....5 mg!

So, who will do better, KSI-301 or 8mg-Eylea?

PS: Remember GILD *methodology* in life-cycle management (wait up to the last moment!)?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News